June 1 (Reuters) - Sierra Oncology Inc SRRA.O :
* SIERRA ANNOUNCES PROMISING PRELIMINARY EFFICACY IN SRA737 CLINICAL PROGRAM & OUTLINES POTENTIAL PATH TO REGISTRATION
* SIERRA ONCOLOGY INC - SIERRA REPORTS 30% RESPONSE RATE FOR SRA737+LDG IN ANOGENITAL CANCER
* SIERRA ONCOLOGY - ANTI-CANCER ACTIVITY DEMONSTRATED ACROSS MULTIPLE INDICATIONS & GENETIC CONTEXTS IN PRELIMINARY PHASE 1/2 DATA PRESENTATIONS AT ASCO